Firefly Neuroscience Inc. (AIFF) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, AIFF scores 36 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 8 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. For an investor, this pillar signals that the business is not currently generating returns on capital or free cash flow to shareholders.
• Whale 13F Flow: 5 / 20. The pillar reflects institutional accumulation and options positioning. A low score indicates limited evidence of supportive institutional demand in the source data.
• Insider Conviction: 5 / 20. Per the rating, this reflects SEC Form 4 and Congressional PTR cluster flow. A low score indicates weak insider-signal support.
• Macro Regime Fit: 7 / 20. The rating cites a beta of 1.0 and sector sensitivity. The pillar suggests the stock's market sensitivity offers no offsetting defensive characteristic.
• Forensic Balance Sheet: 11 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5. This is the strongest pillar, but still below midpoint.

Taken together, the investor implication is that the upside case rests on a future inflection in cash generation that the reported figures do not yet show. The valuation tradeoff is that a $16.2M market capitalization against reported operating losses leaves little margin for execution error, and the balance-sheet pillar, while the strongest, does not offset weak cash-flow and flow signals. This is an analytical reading of the rating, not a recommendation.

Firefly Neuroscience Inc. (AIFF) is a NASDAQ-listed issuer in the Technology sector, operating in Computer Software: Prepackaged Software. Per the profile, the company is classified within this industry with a market capitalization of $0.0B. The source data does not describe specific products, customers, or revenue model beyond the news headlines referenced in the catalysts section.

Per the SEC financials, the company reported operating losses in each period shown, with a gross margin of 56.5%, an operating margin of -60%, and a net margin of -60%. ROIC is -35% per the market data. The Altman Z-Score of 2.5, Piotroski F-Score of 4/9, and Debt/Equity of 0.5 are cited within the Roarable RQD rating's forensic balance-sheet pillar. Reported cash for FY 2025 is $2.7M, while cash and debt are not available in source data for the prior periods.

• Versus Platform commercial availability: A MARKET WIRE item reports the commercial availability of the Versus Platform (YELLOW signal).
• Series A financing: A CATALYST item reports a $20M Series A raise to build a new standard for safety (GREEN signal).
• BCI strategy update: Multiple items reference an updated brain-computer interface strategy, including an EEG/ERP foundation model initiative (YELLOW signals).
• Headset demonstration: A MARKET WIRE item describes a headset that lets users influence flight and driving simulations with brainwaves (YELLOW signal).

Risk watch: the source data contains no quantified revenue guidance tied to these items. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies are not available in source data. Sector correlations are not available in source data beyond the classification of Technology / Computer Software: Prepackaged Software. An investor should watch whether commercial traction for the Versus Platform translates into reported revenue, since FY 2025 revenue of $1.1M remains small relative to the net loss of $-19.9M.

• What is the revenue contribution of the Versus Platform, and does it appear in reported figures?
• What are the cash and debt balances for FY 2024 and FY 2023, which are marked N/A?
• What is the runway implied by the $2.7M FY 2025 cash balance relative to the $-8.2M FCF?
• What drove the Series A raise, and what are its terms and dilution implications?
• What is the basis for the reported EPS of N/A and the absence of TTM P/E and EPS?